|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Oral contraceptives and breast cancer in northern Italy. Final report from a |
| Tavani A; Negri E; Franceschi S; Parazzini F; La Vecchia C |
| BRITISH JOURNAL OF CANCER. 1993 Sep;68(3):568-71. |
| To assess the relation between oral contraceptive (OC) use and breast cancer, the authors analyzed data from a |
| case-control study conducted in northern Italy between 1983 and 1991 on 2309 cases below age 60 and 1928 |
| controls admitted to a hospital for acute diseases unrelated to OC use and to any of the known or potential risk |
| factors for breast cancer. OC use was reported by 16% of cases and 14% of controls. The multivariate relative risk |
| (RR) for ever vs. never use of combination OCs was 1.2 (95% confidence interval [CI] 1.0-1.4). However, there was no |
| trend in risk with duration. The RR was elevated for very short use, but declined to 0.8 (95% CI = 0.5-1.0) for five or |
| more years of use. No noteworthy relationship was found for other major measures of OC use, although RR |
| estimates were above unity for women who had stopped use less than 5 years before (RR = 1.5, 95% CI = 1.1-2.0), |
| started use less than 10 years before (RR = 1.3, 95% CI = 1.0-1.9), started when 25 or more years old (RR = 1.4, 95% |
| CI = 1.1-1.7), or after first birth (RR = 1.2, 95% CI = 1.0-1.5). No interaction was observed between OC use and family |
| history of breast cancer, parity, and age at first birth. A separate analysis of 373 cases and 456 controls below age |
| 40 showed no association with ever use (RR = 0.9, 95% CI = 0.6-1.2). (PubHealth.info Document ID: CONT2T 4562- |
| PubHealth.info NOTE: The author(s) of this article titled, "Oral contraceptives and breast cancer in northern Italy. |
| Final report from a case-control study.", is(are) Tavani A; Negri E; Franceschi S; Parazzini F; La Vecchia C. The |
| source of this article is "BRITISH JOURNAL OF CANCER. 1993 Sep;68(3):568-71.". This article was published in |
| 1993 in English language(s). (PubHealth.info® Document ID: CONT2T 4562-06. All rights reserved with |
| PubHealth.info) PIN: 9562 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
